Skip to main content

Papadimitriou Evangelia

Professor, Molecular Pharmacology

Section of Pharmacology - Biosciences

Director, Postgraduate Studies Program “Drug Discovery & Development”

 

Studies

1985-1989:  Department of Pharmacy, School of Health Sciences, University of Patras, Patras, Greece; Degree: B. Pharm
1990-1994Department of Medicine, School of Health Sciences, University of Patras, Patras, Greece; Degree: Ph.D. in Pharmacology

 

Positions 

  • 2015-present: Professor of Molecular Pharmacology, Department of Pharmacy, University of Patras, Greece; , 2009-2015: Associate Professor; 2003-2009: Assistant Professor; 1998-2003: Lecturer,
  • January 2015: Visiting Professor at the Academic Unit of Orthopaedic and Trauma Surgery, University of Leeds,
  • 1995-1997: Assistant Professor of Pharmacology at the Department of Nursing, Faculty of Professions of Health and Providence, Higher technological and Educational Institute of Patras, Greece
  • 1991-1994: Research Assistant at the University of Wisconsin Medical School, Milwaukee Clinical Campus, Wisconsin, U.S.A
  • Postdoctoral: School of Health Sciences, University of Patras, Patras, Greece; 1994-1995; School of Natural Sciences, University of Patras, Patras, Greece; 1996; School of Health Sciences, University of Patras, Patras, Greece; 1997-1998 

 

Teaching Activity

Undergraduate Program

  • Pharmacology Ι [PHA-C13-NEW]
  • Pharmacology ΙΙ [PHA-C24-NEW]
  • Molecular Pharmacology [PHA-D23-NEW]
  • Introduction to Pharmaceutical Sciences [PHA-A12 -NEW]

Postgraduate Program “Drug Discovery & Development”

  • Preclinical and Clinical Drug Evaluation [[DPHA_4]
  • Molecular Targets of Drug Action [DPHA_C01]
  • Precision Therapeutics [DPHA_C03]

Postgraduate Program “Cosmetology - Preparation and Evaluation of Cosmetic Products”

  • Ingredients of Cosmetic Products [PHA-COS-13]

 

Research Activities

  • Angiogenesis and tumor growth in vitro and in vivo. Pharmacological studies on the mechanisms involved, and evaluation of new compounds or nanoparticles for their anti-angiogenic and anti-tumor activity.  
  • The biological actions of the heparin-binding growth factor pleiotrophin. Effects on endothelial cell functions, angiogenesis, tumor growth and metastasis, bone cell biology. Signaling and receptors identification. Structure-function studies and development of therapeutic applications.  
  • The role of receptor RPTPbeta/zeta in the cardiovascular and the skeletal system. Structure-function studies. 
  • (+30) 2610 962336

  • This email address is being protected from spambots. You need JavaScript enabled to view it.

Office hours for Students
  • Monday 11.00-13.00
    Friday 11.00-13.00